High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans
Diabetes · 2024
DOI: 10.2337/db23-0201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Sarah M Gray und 10 weiteren Autor:innen. Beteiligte Einrichtung: Duke Molecular Physiology Institute, Duke University, Durham, NC. Hauptthemen laut MEDLINE: Glucagon, Hyperglycemia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Glucagon is generally defined as a counterregulatory hormone with a primary role to raise blood glucose concentrations by increasing endogenous glucose production (EGP) in response to hypoglycemia. However, glucagon has long been known to stimulate insulin release, and recent preclinical findings have supported a paracrine action of glucagon directly on islet β-cells that augments their secretion. In mice, the insulinotropic effect of glucagon is glucose dependent and not present during basal euglycemia. To test the hypothesis that the relative effects of glucagon on hepatic and islet function also vary with blood glucose, a group of healthy subjects received glucagon (100 ng/kg) during fasting glycemia or experimental hyperglycemia (∼150 mg/dL) on 2 separate days. During fasting euglycemia, administration of glucagon caused blood glucose to rise due to increased EGP, with a delayed increase of insulin secretion. When given during experimental hyperglycemia, glucagon caused a rapid, threefold increase in insulin secretion, as well as a more gradual increase in EGP. Under both conditions, insulin clearance was decreased in response to glucagon infusion. The insulinotropic action of glucagon, which is proportional to the degree of blood glucose elevation, suggests distinct physiologic roles in the fasting and prandial states. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Molecular Physiology Institute, Duke University, Durham, NC.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA.
- Department of Clinical Studies-New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square.
- Endocrine Section, VA Puget Sound Health Care System, Seattle.
- Division of Endocrinology, Department of Medicine, Duke University, Durham, NC.
ORCID-Profile: Sarah M Gray, Jenny Tong, Jonathan Campbell
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Gray, S. M., Goonatilleke, E., Emrick, M. A., Becker, J. O., Hoofnagle, A. N., Stefanovski, D., He, W., Zhang, G., Tong, J., Campbell, J., & D'Alessio, D. A. (2024). High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans. Diabetes. https://doi.org/10.2337/db23-0201
Vancouver
Gray SM, Goonatilleke E, Emrick MA, Becker JO, Hoofnagle AN, Stefanovski D, et al. High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans. Diabetes. 2024. doi:10.2337/db23-0201
BibTeX
@article{Gray2024,
author = {Gray, Sarah M and Goonatilleke, Elisha and Emrick, Michelle A and Becker, Jessica O and Hoofnagle, Andrew N and Stefanovski, Darko and He, Wentao and Zhang, Guofang and Tong, Jenny and Campbell, Jonathan and D'Alessio, David A},
title = {High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0201}
}
EUVIMED